Granules India recalls ranitidine tablets from US market

Granules India said that it is voluntarily recalling ranitidine tablets used to treat ulcers of the stomach and intestines.

"Ranitidine is being recalled by various producers from the US market, as they contain unacceptable levels of N — nitrosodimethylamine (NDMA). The voluntary ongoing recall is a class II recall," the company said in a BSE filing.

"The company is in the process of recall from channel partners and the exact quantities are being estimated, " it added.

The company believes that this will not have any material impact on its financials.

Comments

Post a Comment

Popular posts from this blog

Updated Ph. Eur. Chapter on plastic containers

A revised version of Ph. Eur. chapter 3.2.2. Plastic containers and closures for pharmaceutical use has been published in Pharmeuropa, Issue 31.4. The deadline for comments is 31 December 2019. In the revised version the list of commonly used polymers has been replaced with a cross-reference to "Materials used for the manufacture of containers" (Ph. Eur. 3.1 and subsections) to take into account additional materials that will be included in the future (e.g. 3.1.17 "Cyclo-olefin copolymers (COC)" and 3.1.18 "Styrene block copolymers for containers and closures for parenteral preparations and ophthalmic preparations", as previously announced in the Ph. Eur. Work Programme of March 2019). In addition, editorial changes have been made throughout the general chapter, including a change in the French title. Furthermore, in August 2019, a new Ph. Eur. Chapter with the title: 2.4.35 "Extractable elements in plastic materials for pharmaceutical use" has b...
Read more

Dr. Stephen Hahn Nominated to Head FDA

Radiation oncology expert Stephen Hahn, M.D., has been nominated as the new U.S. Food and Drug Administration commissioner. Hahn, 59, is chief medical executive of The University of Texas MD Anderson Cancer Center in Houston, and he has been a professor of radiation oncology there since January 2015, CNN reported. Ned Sharpless, M.D., acting commissioner of the FDA, will return to his role as the director of the U.S. National Cancer Institute, the U.S. Department of Health and Human Services said. The FDA has a $5.7 billion budget and more than 17,000 employees, CNN reported.
Read more